Literature DB >> 24082465

Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls.

Manzoor Ahmad1, Nida Suhail, Tariq Mansoor, Naheed Banu, Shamshad Ahmad.   

Abstract

In the present study, oxidative stress and lymphocytic DNA damage in both pre-op and post-op benign prostrate hyperplasia (BPH) patients with age >50 years was evaluated and compared with normal healthy subjects (controls- without any evidence of disease) of the same sex and age group. From December 2007 to November 2009, oxidative stress in 45 BPH patients were evaluated both before (pre-op patients) and after 7 days of surgery (post-op patients) in terms of measurements of plasma levels of (1) various anti-oxidative enzymes, (2) non-enzymatic antioxidants and (3) malondialdehyde which is a product of lipid peroxidation. The lymphocyte DNA damage was also evaluated by single cell alkaline gel electrophoresis in terms of tail length migration in these patients. These values were compared with their respective control subjects of similar sex and age group. The activities of antioxidant enzymes and the levels of antioxidant, reduced glutathione were found significantly decreased (p < 0.05) in serum samples of pre-operative group of BPH patients as compared to the controls. These altered parameters increased significantly (p < 0.05) and returned to their near normal control values, but not up to baseline values, in post operative patients i.e. after the cancer load was decreased by surgery. Lymphocytic DNA damage was found to be significantly increased in pre-op group as compared to controls and was reduced after surgery in post-op group. The present study therefore, shows significantly increased levels of oxidative stress and DNA damage in BPH patients which were reduced after removal of tumour load. Thus oxidative damage plays an important role in prostate tumourogenesis and timely management of oxidative stress can be of importance in preventing the occurrence of BPH.

Entities:  

Keywords:  Antioxidants; BPH; DNA damage; Lipid peroxidation; Oxidative stress

Year:  2012        PMID: 24082465      PMCID: PMC3477465          DOI: 10.1007/s12291-012-0229-4

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  16 in total

Review 1.  Clinical review 134: The endocrinology of prostate cancer.

Authors:  M E Taplin; S M Ho
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 2.  Prostatic growth: new insights into hormonal regulation.

Authors:  J D McConnell
Journal:  Br J Urol       Date:  1995-07

3.  A simple technique for quantitation of low levels of DNA damage in individual cells.

Authors:  N P Singh; M T McCoy; R R Tice; E L Schneider
Journal:  Exp Cell Res       Date:  1988-03       Impact factor: 3.905

4.  Glutathione S-transferases. The first enzymatic step in mercapturic acid formation.

Authors:  W H Habig; M J Pabst; W B Jakoby
Journal:  J Biol Chem       Date:  1974-11-25       Impact factor: 5.157

5.  Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite.

Authors:  D J Jollow; J R Mitchell; N Zampaglione; J R Gillette
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

6.  Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.

Authors:  P H Gann; J Ma; E Giovannucci; W Willett; F M Sacks; C H Hennekens; M J Stampfer
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

Review 7.  Chemistry, physiology and pathology of free radicals.

Authors:  L Bergendi; L Benes; Z Duracková; M Ferencik
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

8.  Purification and characterization of the flavoenzyme glutathione reductase from rat liver.

Authors:  I Carlberg; B Mannervik
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

9.  Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors.

Authors:  Donald C Malins; Paul M Johnson; Edward A Barker; Nayak L Polissar; Thomas M Wheeler; Katie M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

View more
  17 in total

1.  Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia.

Authors:  Shao-Ling Yang; Ke-Qiang Tang; Wen-Kun Bai; E Shen; Yi-Wen Zhao; Yan-Duan Lin; Shu-Liang Nan; Hu Bing
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

2.  Inhibitory effect of diosgenin on experimentally induced benign prostatic hyperplasia in rats.

Authors:  Jing Chen; Huai-Fen Zhang; Chao-Mei Xiong; Jin-Lan Ruan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

3.  SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.

Authors:  Danyelle Winchester; Luisel Ricks-Santi; Tshela Mason; Muneer Abbas; Robert L Copeland; Desta Beyene; Emmanuel Y Jingwi; Georgia M Dunston; Yasmine M Kanaan
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

4.  Peripheral mononuclear leukocyte DNA damage, plasma prolidase activity, and oxidative status in patients with benign prostatic hyperplasia.

Authors:  Ilhan Gecit; Ismail Meral; Mehmet Aslan; Abdurrahim Kocyigit; Hakim Celik; Abdullah Taskın; Mehmet Kaba; Necip Pirincci; Mustafa Gunes; Kerem Taken; Halit Demir; Mehmet Uyuklu; Kadir Ceylan
Journal:  Redox Rep       Date:  2014-12-31       Impact factor: 4.412

5.  Origanum majorana L. Extract Attenuated Benign Prostatic Hyperplasia in Rat Model: Effect on Oxidative Stress, Apoptosis, and Proliferation.

Authors:  Dalia Mahmoud Abdelmonem Elsherbini; Hailah M Almohaimeed; Mohamed El-Sherbiny; Zuhair M Mohammedsaleh; Nehal M Elsherbiny; Sami A Gabr; Hasnaa Ali Ebrahim
Journal:  Antioxidants (Basel)       Date:  2022-06-11

Review 6.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

7.  Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.

Authors:  Shao-ling Yang; Ke-qiang Tang; Wen-kun Bai; Yi-Wen Zhao; E Shen; Jun-jia Tao; Bing Hu
Journal:  J Endourol       Date:  2013-08       Impact factor: 2.942

8.  Oxidative stress promotes benign prostatic hyperplasia.

Authors:  Paz Vital; Patricia Castro; Michael Ittmann
Journal:  Prostate       Date:  2015-09-29       Impact factor: 4.104

Review 9.  Oxidative stress in prostate hyperplasia and carcinogenesis.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2016-09-08

10.  The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.

Authors:  Woong Jin Bae; Hyo Jung Park; Hye Cheong Koo; Do Ram Kim; U-Syn Ha; Kang Sup Kim; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Sung Yeoun Hwang; Sae Woong Kim
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.